Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E B Wright

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Human Molecular Genetics|September 8, 2020
Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington diseaseGalen E B Wright, Nicholas S Caron, Bernard Ng, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 4, 2020
Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance rangeHailey Findlay Black, Galen E B Wright, Jennifer A Collins, et al.
Pharmacogenomics|August 18, 2010
Characterization of the genetic profile of CYP2C19 in two South African populationsBritt I Drögemöller, Galen E B Wright, Dana J H Niehaus, et al.
Journal of Clinical Pharmacology|November 20, 2018
Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety DatabaseReo Tanoshima, Amna Khan, Agnieszka K Biala, et al.
NPJ Genomic Medicine|May 22, 2021
Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicityErika N Scott, Galen E B Wright, Britt I Drögemöller, et al.
Clinical Pharmacology and Therapeutics|September 16, 2022
Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African PopulationsDavid Twesigomwe, Britt I Drögemöller, Galen E B Wright, et al.
Clinical Pharmacology and Therapeutics|December 4, 2023
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African PopulationsDavid Twesigomwe, Britt I Drögemöller, Galen E B Wright, et al.
BMC Medical Genetics|January 30, 2013
Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort studyTyren M Dodgen, Warren E Hochfeld, Heidi Fickl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Further Investigation of the Role of <i>ACYP2</i> and <i>WFS1</i> Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer PatientsBritt I Drögemöller, Beth Brooks, Carol Critchley, et al.
Pharmacogenetics and Genomics|March 2, 2016
The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patientsBritt I Drögemöller, Robin Emsley, Bonginkosi Chiliza, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Human Molecular Genetics|September 8, 2020
Gene expression profiles complement the analysis of genomic modifiers of the clinical onset of Huntington diseaseGalen E B Wright, Nicholas S Caron, Bernard Ng, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 4, 2020
Frequency of the loss of CAA interruption in the HTT CAG tract and implications for Huntington disease in the reduced penetrance rangeHailey Findlay Black, Galen E B Wright, Jennifer A Collins, et al.
Pharmacogenomics|August 18, 2010
Characterization of the genetic profile of CYP2C19 in two South African populationsBritt I Drögemöller, Galen E B Wright, Dana J H Niehaus, et al.
Journal of Clinical Pharmacology|November 20, 2018
Analyses of Adverse Drug Reactions-Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety DatabaseReo Tanoshima, Amna Khan, Agnieszka K Biala, et al.
NPJ Genomic Medicine|May 22, 2021
Transcriptome-wide association study uncovers the role of essential genes in anthracycline-induced cardiotoxicityErika N Scott, Galen E B Wright, Britt I Drögemöller, et al.
Clinical Pharmacology and Therapeutics|September 16, 2022
Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African PopulationsDavid Twesigomwe, Britt I Drögemöller, Galen E B Wright, et al.
Clinical Pharmacology and Therapeutics|December 4, 2023
Characterization of CYP2B6 and CYP2A6 Pharmacogenetic Variation in Sub-Saharan African PopulationsDavid Twesigomwe, Britt I Drögemöller, Galen E B Wright, et al.
BMC Medical Genetics|January 30, 2013
Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort studyTyren M Dodgen, Warren E Hochfeld, Heidi Fickl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Further Investigation of the Role of <i>ACYP2</i> and <i>WFS1</i> Pharmacogenomic Variants in the Development of Cisplatin-Induced Ototoxicity in Testicular Cancer PatientsBritt I Drögemöller, Beth Brooks, Carol Critchley, et al.
Pharmacogenetics and Genomics|March 2, 2016
The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patientsBritt I Drögemöller, Robin Emsley, Bonginkosi Chiliza, et al.
Pageof 7